We came across a bullish thesis on Sarepta Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment ...

Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025. He was an easy selection, but unlike some ...

Detailed price information for Elevance Health Inc (ELV-N) from The Globe and Mail including charting and trades.

Investor attention has returned to Sarepta Therapeutics amid reports of the biotech firm's vigorous legal strategy to protect ...

Solid Biosciences Inc. (NASDAQ:SLDB) develops therapies for neuromuscular and cardiac diseases in the US. In addition, the ...

The Trump administration is currently questioning the role of science in maintaining the nation’s health, economy and global ...

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.

Bearish flow noted in Sarepta (SRPT) with 2,510 puts trading, or 1.9x expected. Most active are Jan-27 20 puts and Jan-26 30 puts, with total ...

After a challenging year for Sarepta Therapeutics, its chief executive has received his first equity grant in about eight ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.